A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response

Laurens Kruidenier, Chun‐wa Chung(GlaxoSmithKline (United Kingdom)), Zhongjun Cheng(Memorial Sloan Kettering Cancer Center), John Liddle(GlaxoSmithKline (United Kingdom)), KaHing Che(Genomics England), Gérard Joberty, Marcus Bantscheff, C. Bountra(Genomics England), Angela Bridges(GlaxoSmithKline (United Kingdom)), Hawa Diallo(GlaxoSmithKline (United Kingdom)), Dirk Eberhard, Sue Hutchinson(GlaxoSmithKline (United Kingdom)), Emma J. Jones(GlaxoSmithKline (United Kingdom)), Roy Katso(GlaxoSmithKline (United Kingdom)), Melanie Leveridge(GlaxoSmithKline (United Kingdom)), Palwinder K. Mander(GlaxoSmithKline (United Kingdom)), J. Mosley(GlaxoSmithKline (United Kingdom)), César Ramírez-Molina(GlaxoSmithKline (United Kingdom)), Paul Rowland(GlaxoSmithKline (United Kingdom)), Christopher J. Schofield(University of Oxford), Robert J. Sheppard(GlaxoSmithKline (United Kingdom)), Julia E. Smith(GlaxoSmithKline (United Kingdom)), Catherine Swales(University of Oxford), Robert D. Tanner(GlaxoSmithKline (United Kingdom)), Pamela J. Thomas(GlaxoSmithKline (United Kingdom)), Anthony Tumber(Genomics England), Gerard Drewes, Udo Oppermann(University of Oxford), Dinshaw J. Patel(Memorial Sloan Kettering Cancer Center), Kevin Lee(GlaxoSmithKline (United Kingdom)), David M. Wilson(GlaxoSmithKline (United Kingdom))
Nature
July 27, 2012
10.1038/nature11262
Cited by 955Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis